Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2772) 2772
Publication (896) 896
Paper (481) 481
Report (80) 80
Data Set (23) 23
Book Chapter (5) 5
Book / eBook (4) 4
Book Review (4) 4
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
experiment (1177) 1177
high energy physics (1003) 1003
physical sciences (897) 897
fysik (896) 896
natural sciences (857) 857
naturvetenskap (857) 857
physics (786) 786
physics of elementary particles and fields (653) 653
phenomenology (617) 617
high energy physics - experiment (555) 555
hadron-hadron scattering (544) 544
particle physics (479) 479
subatomic physics (450) 450
subatomär fysik (450) 450
physics - high energy physics - experiment (442) 442
physics, particles & fields (406) 406
nuclear experiment (384) 384
cern lhc coll (261) 261
experimental results (254) 254
elementary particles, quantum field theory (246) 246
quantum field theories, string theory (246) 246
[ phys.hexp ] physics [physics]/high energy physics - experiment [hep-ex] (229) 229
humans (193) 193
particle physics - experiment (183) 183
male (179) 179
scattering [p p] (177) 177
物理学 (174) 174
collisions (167) 167
astrophysics (164) 164
parton distributions (158) 158
detectors (151) 151
astronomy, astrophysics and cosmology (148) 148
high energy astrophysical phenomena (141) 141
colliding beams [p p] (138) 138
astronomy & astrophysics (136) 136
prostate cancer (136) 136
8000 gev-cms (133) 133
nuclear energy (131) 131
oncology (128) 128
measurement science and instrumentation (126) 126
classical and quantum gravitation, relativity theory (123) 123
nuclear physics, heavy ions, hadrons (123) 123
quantum physics (123) 123
science & technology (117) 117
[phys.hexp]physics [physics]/high energy physics - experiment [hep-ex] (113) 113
index medicus (111) 111
nuclear and high energy physics (111) 111
supersymmetry (111) 111
ciências físicas [ciências naturais] (110) 110
large hadron collider (107) 107
regular - experimental physics (103) 103
middle aged (101) 101
aged (100) 100
settore fis/01 - fisica sperimentale (95) 95
regular article - experimental physics (91) 91
physics and astronomy (89) 89
atlas (86) 86
settore fis/04 - fisica nucleare e subnucleare (83) 83
decay (81) 81
prostatic neoplasms - radiotherapy (81) 81
engineering (79) 79
p p: scattering (78) 78
physics, nuclear (77) 77
pair production (76) 76
radiotherapy (74) 74
radiology, nuclear medicine & medical imaging (73) 73
cancer (72) 72
p p: colliding beams (71) 71
analysis (69) 69
hadron colliders (69) 69
lhc (69) 69
model (68) 68
instrumentation and detectors (65) 65
13000 gev-cms (61) 61
prostatic neoplasms - pathology (57) 57
searching (56) 56
physik (54) 54
quarks (54) 54
top physics (54) 54
background (53) 53
beyond standard model (53) 53
higgs physics (53) 53
física (52) 52
radiation-therapy (52) 52
research (52) 52
transverse momentum (51) 51
treatment outcome (50) 50
hep (49) 49
bosons (48) 48
weak (48) 48
luminosity (47) 47
electroweak interaction (46) 46
ex (46) 46
jets (46) 46
particle accelerators (46) 46
conformal radiotherapy (43) 43
transverse momentum dependence (43) 43
confidence intervals (42) 42
hadron (42) 42
measurement (42) 42
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text In Regard to Spratt
by Wilkins, Anna C and Gusterson, Barry and Dearnaley, David P and Hall, Emma and Somaiah, Navita
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 12/2018, Volume 102, Issue 5, pp. 1596 - 1597
Biomarkers | Prostatic Neoplasms | Male | Prognosis | Humans
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
by James, Nicholas D, Prof and Sydes, Matthew R, MSc and Clarke, Noel W, Prof and Mason, Malcolm D, Prof and Dearnaley, David P, Prof and Spears, Melissa R, MSc and Ritchie, Alastair W S, MD and Parker, Christopher C, MD and Russell, J Martin, FRCR and Attard, Gerhardt, MD PhD and de Bono, Johann, Prof and Cross, William, PhD and Jones, Rob J, Prof and Thalmann, George, Prof and Amos, Claire, PhD and Matheson, David, PhD and Millman, Robin and Alzouebi, Mymoona, FRCR and Beesley, Sharon, FRCR and Birtle, Alison J, MD and Brock, Susannah, FRCR and Cathomas, Richard, MD and Chakraborti, Prabir, FRCR and Chowdhury, Simon, MD and Cook, Audrey, FRCR and Elliott, Tony, PhD and Gale, Joanna, DM and Gibbs, Stephanie, FRCR and Graham, John D, FRCP and Hetherington, John, FRCS[Eng] and Hughes, Robert, FRCR and Laing, Robert, FRCR and McKinna, Fiona, FRCR and McLaren, Duncan B, FRCR, FRCP[Ed] and O'Sullivan, Joe M, Prof and Parikh, Omi, FRCR and Peedell, Clive, FRCR and Protheroe, Andrew, PhD and Robinson, Angus J, FRCR and Srihari, Narayanan, MD and Srinivasan, Rajaguru, FRCR and Staffurth, John, MD and Sundar, Santhanam, FRCR and Tolan, Shaun, MD and Tsang, David, MCRP and Wagstaff, John, Prof and Parmar, Mahesh K B, Prof and STAMPEDE Investigators and STAMPEDE investigators
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10024, pp. 1163 - 1177
Summary Background Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled... 
Internal Medicine | ANDROGEN-DEPRIVATION THERAPY | MEDICINE, GENERAL & INTERNAL | PREDNISONE | DESIGN | MITOXANTRONE | CABAZITAXEL | CLINICAL-TRIALS | OPEN-LABEL | CHEMOTHERAPY | ENZALUTAMIDE | ESTRAMUSTINE | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Aged, 80 and over | Adult | Diphosphonates - adverse effects | Prostatic Neoplasms - drug therapy | Taxoids - adverse effects | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Imidazoles - adverse effects | Docetaxel | Kaplan-Meier Estimate | Treatment Outcome | Diphosphonates - administration & dosage | Zoledronic Acid | Disease Progression | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Survival analysis | Medical prognosis | Clinical trials | Hormone replacement therapy | Metastasis | Prostate cancer | Cancer therapies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
by James, Nicholas D and de Bono, Johann S and Spears, Melissa R and Clarke, Noel W and Mason, Malcolm D and Dearnaley, David P and Ritchie, Alastair W.S and Amos, Claire L and Gilson, Clare and Jones, Rob J and Matheson, David and Millman, Robin and Attard, Gerhardt and Chowdhury, Simon and Cross, William R and Gillessen, Silke and Parker, Christopher C and Russell, J. Martin and Berthold, Dominik R and Brawley, Chris and Adab, Fawzi and Aung, San and Birtle, Alison J and Bowen, Jo and Brock, Susannah and Chakraborti, Prabir and Ferguson, Catherine and Gale, Joanna and Gray, Emma and Hingorani, Mohan and Hoskin, Peter J and Lester, Jason F and Malik, Zafar I and McKinna, Fiona and McPhail, Neil and Money-Kyrle, Julian and O’Sullivan, Joe and Parikh, Omi and Protheroe, Andrew and Robinson, Angus and Srihari, Narayanan N and Thomas, Carys and Wagstaff, John and Wylie, James and Zarkar, Anjali and Parmar, Mahesh K.B and Sydes, Matthew R and STAMPEDE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 4, pp. 338 - 351
The addition of abiraterone and prednisolone to standard androgen-deprivation therapy as the first treatment for patients with locally advanced or metastatic... 
ZOLEDRONIC ACID | SURVIVAL | MEDICINE, GENERAL & INTERNAL | PLUS PREDNISONE | CONTROL ARM | STAMPEDE TRIAL | OPEN-LABEL | MULTISTAGE | RANDOMIZED CONTROLLED-TRIAL | DOCETAXEL | MULTIARM | Prednisolone - adverse effects | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms - radiotherapy | Prednisolone - administration & dosage | Prostatic Neoplasms - surgery | Humans | Middle Aged | Abiraterone Acetate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Abiraterone Acetate - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Prostatic Neoplasms - drug therapy | Androgen suppression therapy | Usage | Care and treatment | Prostate cancer | Prednisolone | Medical research | Prostate-specific antigen | Clinical trials | Endocrine therapy | Oncology | Metastasis | Radiation therapy | Cancer therapies | Metastases | Mens health | Androgens | Medical prognosis | Death | Prostate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array
by Eeles, Rosalind A and Olama, Ali Amin Al and Benlloch, Sara and Saunders, Edward J and Leongamornlert, Daniel A and Tymrakiewicz, Malgorzata and Ghoussaini, Maya and Luccarini, Craig and Dennis, Joe and Jugurnauth-Little, Sarah and Dadaev, Tokhir and Neal, David E and Hamdy, Freddie C and Donovan, Jenny L and Muir, Ken and Giles, Graham G and Severi, Gianluca and Wiklund, Fredrik and Gronberg, Henrik and Haiman, Christopher A and Schumacher, Fredrick and Henderson, Brian E and Le Marchand, Loic and Lindstrom, Sara and Kraft, Peter and Hunter, David J and Gapstur, Susan and Chanock, Stephen J and Berndt, Sonja I and Albanes, Demetrius and Andriole, Gerald and Schleutker, Johanna and Weischer, Maren and Canzian, Federico and Riboli, Elio and Key, Tim J and Travis, Ruth C and Campa, Daniele and Ingles, Sue A and John, Esther M and Hayes, Richard B and Pharoah, Paul D. P and Pashayan, Nora and Khaw, Kay-Tee and Stanford, Janet L and Ostrander, Elaine A and Signorello, Lisa B and Thibodeau, Stephen N and Schaid, Dan and Maier, Christiane and Vogel, Walther and Kibel, Adam S and Cybulski, Cezary and Lubinski, Jan and Cannon-Albright, Lisa and Brenner, Hermann and Park, Jong Y and Kaneva, Radka and Batra, Jyotsna and Spurdle, Amanda B and Clements, Judith A and Teixeira, Manuel R and Dicks, Ed and Lee, Andrew and Dunning, Alison M and Baynes, Caroline and Conroy, Don and Maranian, Melanie J and Ahmed, Shahana and Govindasami, Koveela and Guy, Michelle and Wilkinson, Rosemary A and Sawyer, Emma J and Morgan, Angela and Dearnaley, David P and Horwich, Alan and Huddart, Robert A and Khoo, Vincent S and Parker, Christopher C and Van As, Nicholas J and Woodhouse, Christopher J and Thompson, Alan and Dudderidge, Tim and Ogden, Chris and Cooper, Colin S and Lophatananon, Artitaya and Cox, Angela and Southey, Melissa C and Hopper, John L and English, Dallas R and Aly, Markus and Adolfsson, Jan and Xu, Jiangfeng and Zheng, Siqun L and Yeager, Meredith and Kaaks, Rudolf and Diver, W Ryan and Gaudet, Mia M and Stern, Mariana C and Corral, Roman and ... and UK Genetic Prostate Canc Study and Australian Prostate Canc and PRACTICAL Prostate Canc Assoc Grp and COGS-Canc Res UK GWAS-ELLIPSE Part and UK ProtecT Prostate Testing Canc and COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative and UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology and UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators and Australian Prostate Cancer Bioresource and PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium and The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium and The Australian Prostate Cancer Bioresource and The UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators and The COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative and The UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
Nature Genetics, ISSN 1061-4036, 04/2013, Volume 45, Issue 4, pp. 385 - 391
Prostate cancer is the most frequently diagnosed cancer in males in developed countries. To identify common prostate cancer susceptibility alleles, we... 
VARIANTS | PREDISPOSITION | MEN | GENETICS & HEREDITY | MUTATIONS | HOXB13 | GENOME-WIDE ASSOCIATION | Prostatic Neoplasms - pathology | Genetic Predisposition to Disease | Genome-Wide Association Study | Meta-Analysis as Topic | Oligonucleotide Array Sequence Analysis | Humans | Risk Factors | Genetic Loci - genetics | Prostatic Neoplasms - etiology | Cooperative Behavior | Genotype | Male | Case-Control Studies | Polymorphism, Single Nucleotide - genetics | Quantitative trait loci | Genetic susceptibility | Genetic aspects | Research | Prostate cancer | Identification and classification | Risk factors | Studies | Confidence intervals | Genotype & phenotype | Genealogy | Quality control | Cell cycle | Genomes | DNA repair | Deoxyribonucleic acid--DNA | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial
by Dearnaley, David P, Prof and Jovic, Gordana, PhD and Syndikus, Isabel, FRCR and Khoo, Vincent, FRCR and Cowan, Richard A, FRCR and Graham, John D, FRCR and Aird, Edwin G, PhD and Bottomley, David, FRCR and Huddart, Robert A, FRCR and Jose, Chakiath C, FRANZCR and Matthews, John H L, FRANZCR and Millar, Jeremy L, FRANZCR and Murphy, Claire, BSc and Russell, J Martin, FRCR and Scrase, Christopher D, FRCR and Parmar, Mahesh K B, Prof and Sydes, Matthew R, MSc
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 4, pp. 464 - 473
Summary Background The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with... 
Hematology, Oncology and Palliative Medicine | ANDROGEN-DEPRIVATION THERAPY | EXTERNAL-BEAM RADIOTHERAPY | LOW-RISK | ONCOLOGY | NEOADJUVANT HORMONE-THERAPY | RATE BRACHYTHERAPY | MEN | RADICAL PROSTATECTOMY | TOXICITY | SUPPRESSION | RADIATION-THERAPY | Prostatic Neoplasms - radiotherapy | Humans | Middle Aged | Male | Time Factors | Aged, 80 and over | Prostatic Neoplasms - blood | Dose Fractionation | Neoadjuvant Therapy | Kallikreins - blood | Chemotherapy, Adjuvant | Prostatic Neoplasms - pathology | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Disease Progression | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Disease-Free Survival | Radiotherapy, Conformal - mortality | Intention to Treat Analysis | Androgen Antagonists - therapeutic use | Radiotherapy, Conformal - adverse effects | Aged | Neoplasm Staging | Clinical trials | Radiotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
by Parker, Christopher C and James, Nicholas D and Brawley, Christopher D and Clarke, Noel W and Hoyle, Alex P and Ali, Adnan and Ritchie, Alastair W S and Attard, Gerhardt and Chowdhury, Simon and Cross, William and Dearnaley, David P and Gillessen, Silke and Gilson, Clare and Jones, Robert J and Langley, Ruth E and Malik, Zafar I and Mason, Malcolm D and Matheson, David and Millman, Robin and Russell, J Martin and Thalmann, George N and Amos, Claire L and Alonzi, Roberto and Bahl, Amit and Birtle, Alison and Din, Omar and Douis, Hassan and Eswar, Chinnamani and Gale, Joanna and Gannon, Melissa R and Jonnada, Sai and Khaksar, Sara and Lester, Jason F and O'Sullivan, Joe M and Parikh, Omi A and Pedley, Ian D and Pudney, Delia M and Sheehan, Denise J and Srihari, Narayanan Nair and Tran, Anna T H and Parmar, Mahesh K B and Sydes, Matthew R and Systemic Therapy Adv Metastatic and Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators
The Lancet, ISSN 0140-6736, 12/2018, Volume 392, Issue 10162, pp. 2353 - 2366
Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that... 
SURVIVAL | MEDICINE, GENERAL & INTERNAL | MEN | RADICAL PROSTATECTOMY | TIME | BONE | ANDROGEN DEPRIVATION THERAPY | RADIATION-THERAPY | Prostatic Neoplasms - pathology | Prostatic Neoplasms - radiotherapy | Lymph Nodes - pathology | Prostatic Neoplasms - surgery | Standard of Care | Humans | Middle Aged | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Gonadotropin-Releasing Hormone - antagonists & inhibitors | Radiotherapy - adverse effects | Orchiectomy | Disease-Free Survival | Neoplasm Metastasis | Survival Analysis | Docetaxel - therapeutic use | Aged | Gonadotropin-Releasing Hormone - agonists | Prostatic Neoplasms - drug therapy | Metastasis | Radiotherapy | Prostate cancer | Analysis | Drug abuse | Substance abuse treatment | Prostate-specific antigen | Radiation | Bladder | Subgroups | Metastases | Randomization | Motivation | Nonsteroidal anti-inflammatory drugs | Urogenital system | Medical research | Aspirin | Deprivation | Hazards | Inflammation | Radiation therapy | Patients | Survival | Androgens | Hypotheses | Medical prognosis | Men | Prostate | Cancer | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.11.010
by Tree, Alison C and van As, Nicholas J and Dearnaley, David P
European Urology, ISSN 0302-2838, 2016
Urology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Hypofractionated radiotherapy in prostate cancer
by Dearnaley, David P
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 237 - 238
Hematology, Oncology and Palliative Medicine | TOXICITY | THERAPY | RANDOMIZED CONTROLLED-TRIAL | ONCOLOGY | ALPHA/BETA RATIO | Male Urogenital Diseases - etiology | Prostatic Neoplasms - radiotherapy | Humans | Gastrointestinal Diseases - etiology | Dose Fractionation | Male | Radiation Injuries - etiology | Radiotherapy | Prostate cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Stereotactic body radiotherapy for oligometastases
by Tree, Alison C, Dr and Khoo, Vincent S, MD and Eeles, Rosalind A, Prof and Ahmed, Merina, MD and Dearnaley, David P, Prof and Hawkins, Maria A, MD and Huddart, Robert A, PhD and Nutting, Christopher M, Prof and Ostler, Peter J, FRCR and van As, Nicholas J, FRCR
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. e28 - e37
Summary The management of metastatic solid tumours has historically focused on systemic treatment given with palliative intent. However, radical surgical... 
Hematology, Oncology and Palliative Medicine | LONG-TERM | BREAST-CANCER | LUNG | ONCOLOGY | ADRENAL-GLAND METASTASES | COLORECTAL-CANCER | INTENSITY-MODULATED RADIOTHERAPY | PHASE-II | LOCAL-CONTROL | RADIATION-THERAPY SBRT | SPINAL METASTASES | Disease-Free Survival | Lung Neoplasms - secondary | Neoplasm Metastasis - radiotherapy | Neoplasm Metastasis - pathology | Humans | Liver Neoplasms - radiotherapy | Lung Neoplasms - radiotherapy | Dose Fractionation | Radiotherapy, Image-Guided | Liver Neoplasms - secondary | Radiosurgery - methods | Research | Radiotherapy | Nuclear radiation | Oncology, Experimental | Health care reform | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy
by Crook, Juanita M and O'Callaghan, Christopher J and Duncan, Graeme and Dearnaley, David P and Higano, Celestia S and Horwitz, Eric M and Frymire, Eliot and Malone, Shawn and Chin, Joseph and Nabid, Abdenour and Warde, Padraig and Corbett, Thomas and Angyalfi, Steve and Goldenberg, S. Larry and Gospodarowicz, Mary K and Saad, Fred and Logue, John P and Hall, Emma and Schellhammer, Paul F and Ding, Keyue and Klotz, Laurence
The New England Journal of Medicine, ISSN 0028-4793, 09/2012, Volume 367, Issue 10, pp. 895 - 903
Androgen-deprivation therapy for prostate cancer has side effects. In this study, intermittent androgen-deprivation therapy was associated with a survival rate... 
DEPRIVATION THERAPY | MEDICINE, GENERAL & INTERNAL | BONE-MINERAL DENSITY | CLINICAL-TRIALS | ENDOCRINE THERAPY | FOLLOW-UP | ADVANCED PROSTATE-CANCER | CARCINOMA | COGNITIVE FUNCTION | ANTIGEN | Prostatic Neoplasms - radiotherapy | Prognosis | Drug Administration Schedule | Follow-Up Studies | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Male | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Aged, 80 and over | Quality of Life | Adult | Aged | Androgen Antagonists - administration & dosage | Chemotherapy, Adjuvant | Testosterone - blood | Androgen Antagonists - adverse effects | Prostatic Neoplasms - drug therapy | Care and treatment | Prostate-specific antigen | Patient outcomes | Analysis | Diagnosis | Research | Radiotherapy | Prostate cancer | Health aspects | Quality of life | Testosterone | Castration | Men | Fatigue | Radiation therapy | Cancer therapies | Survival | Patients | Prostate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights